Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision genome editing biotech developing base and prime editors for rare genetic diseases; improved specificity over first-generation CRISPR competing with Beam Therapeutics and Intellia.
Veda Bio is a biotechnology company developing novel therapeutics for rare genetic diseases and cancer using its proprietary precision genome editing platform — enabling targeted genetic corrections with greater specificity and reduced off-target editing compared to first-generation CRISPR tools. Founded in 2019 and headquartered in Seattle, Washington, Veda Bio was founded by genome editing pioneers and has raised early-stage funding to develop its differentiated editing technology platform.\n\nVeda Bio's platform focuses on delivering precision genetic medicine that can address root causes of genetic diseases rather than managing symptoms. The company's approach aims to improve on first-generation CRISPR-Cas9 by developing base editors and prime editors that can make specific genetic corrections (single letter DNA changes, small insertions or deletions) without introducing double-strand DNA breaks that create higher off-target editing risk. This precision is critical for therapeutic applications where off-target genomic changes could have serious safety consequences.\n\nIn 2025, Veda Bio operates in the competitive genome editing therapeutics space alongside Intellia Therapeutics, Beam Therapeutics (base editing pioneer), Prime Medicine, and CRISPR Therapeutics. The genome editing field experienced a landmark moment in 2023 with the FDA approval of Casgevy (the first CRISPR-based therapy, for sickle cell disease and beta-thalassemia, developed by Vertex and CRISPR Therapeutics) — validating the genome editing therapeutic modality and creating competitive pressure for improved precision editing platforms. Veda Bio's 2025 strategy focuses on advancing lead programs in rare genetic indications through preclinical development toward IND applications, publishing research to establish scientific credibility, and exploring partnerships or licensing with larger biopharmaceuticals for clinical development.
NYC YC "TurboTax for Medicaid" at $22M total ($18M a16z Series A Jul 2025) with AI + live navigators reducing member churn 15% addressing $50B administrative waste; 12-person team competing with Maximus for Medicaid enrollment technology.
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowitz (a16z) with BoxGroup, and a $4 million seed in November 2023 from YC, BoxGroup, and angel investors including founders of Zocdoc, PillPack, and Cityblock Health — providing Medicaid health plans, providers, and state governments with an AI-powered Medicaid navigation platform that pairs AI automation with live human navigators to guide beneficiaries through enrollment, coverage maintenance, and renewal workflows, reducing member churn by 15% and addressing the $50 billion in administrative waste that the US Medicaid system generates annually. Founded in 2023 by Cydney Kim, Nikita Singareddy, and Ben Wesner, Fortuna Health operates with a 12-person team and has been described as "TurboTax for Medicaid."
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.